Trial Profile
A Phase III Multicenter, Randomized, Double-Blind, Parallel-Group, Sham-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell as an Adjunct to Good Wound Care in Lower Extremity Chronic Ulcers in Adults With Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Dec 2015
Price :
$35
*
At a glance
- Drugs Leukocyte cell therapy Leap Therapeutics (Primary)
- Indications Diabetic foot ulcer
- Focus Registrational; Therapeutic Use
- Sponsors MacroCure
- 03 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 27 Oct 2015 According to a Macroocure media release, Primary endpoint has not been met. (Proportion of patients with complete healing/closure of their target ulcer)
- 25 Sep 2015 Planned End Date changed from 1 Aug 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov.